PP1815

AXP000230.1 · Phage therapy

Platform
single phage, solution for injection
Originator
Pherecydes Pharma
Sponsor
Phaxiam Therapeutics

Names

NameTypeSource
PP1815preferred name, codecurator, curator

Virus

Role
Phage
Family
Caudoviricetes
Virus
Staphylococcus aureus bacteriophage
Replication
replicating
Route
intravenous, inhaled
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06605651Proof of Concept Study to Assess Safety and Efficacy of Phage Therapy in Hip or Knee Prosthetic Joint Infections Due to Staphylococcus Aureus Treated by DAIR.Not yet recruitingPhase 22026-072028-03100Hip Prosthesis Infection; Knee Prosthesis Infection

Recent changes

No changes recorded in its trials yet.

Notes

Anti-Staphylococcus aureus phage, solution for injection, used alongside PP1493 under French compassionate access and in PhagoDAIR I NCT05369104 and PhagoDAIR II NCT06605651. See PP1493 for why the two are separate programs.

How to cite

PP1815 (AXP000230.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000230.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.